Cargando…
Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
BACKGROUND AND AIMS: To clarify the relationship between metabolic dysfunction‐associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). METHODS: The participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFL...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847128/ https://www.ncbi.nlm.nih.gov/pubmed/34561962 http://dx.doi.org/10.1111/jdi.13678 |
_version_ | 1784651983578202112 |
---|---|
author | Hashimoto, Yoshitaka Hamaguchi, Masahide Okamura, Takuro Nakanishi, Naoko Obora, Akihiro Kojima, Takao Fukui, Michiaki |
author_facet | Hashimoto, Yoshitaka Hamaguchi, Masahide Okamura, Takuro Nakanishi, Naoko Obora, Akihiro Kojima, Takao Fukui, Michiaki |
author_sort | Hashimoto, Yoshitaka |
collection | PubMed |
description | BACKGROUND AND AIMS: To clarify the relationship between metabolic dysfunction‐associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). METHODS: The participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFLD was defined as having both FLD and MD, whereas CKD was defined as having an estimated glomerular filtration rate of <60 mL/min/1.73 m(2) and/or proteinuria. RESULTS: In this cross‐sectional study of 27,371 participants, the proportions of those in the non‐FLD without MD, non‐FLD with MD, FLD without MD, and MAFLD groups were 48.7, 28.2, 2.3, and 20.8%, respectively. Compared with non‐FLD without MD, MAFLD was associated with the risk of CKD (adjusted odds ratio 1.83 [1.66–2.01], P < 0.001), whereas FLD without MD was not (1.02 [0.79–1.33], P = 0.868). Moreover, compared with FLD without MD, MAFLD was associated with the risk of CKD (1.19 [1.09–1.31], P < 0.001). In this retrospective cohort study, 16,938 of 27,371 participants underwent a median 4.6 (2.0–8.1) years follow‐up, and incident data of non‐FLD without MD, non‐FLD with MD, FLD without MD, and MAFLD were 21.0, 31.1, 26.1, and 31.1 cases per 1,000 person‐years, respectively. Compared with the non‐FLD without MD, MAFLD was associated with the risk of incident CKD (adjusted hazard ratio 1.24 [1.14–1.36], P < 0.001), whereas FLD without MD was not (1.11 [0.85–1.41], P = 0.433). CONCLUSIONS: MAFLD was associated with a risk of CKD, whereas FLD without MD was not a risk for CKD. |
format | Online Article Text |
id | pubmed-8847128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88471282022-02-25 Metabolic associated fatty liver disease is a risk factor for chronic kidney disease Hashimoto, Yoshitaka Hamaguchi, Masahide Okamura, Takuro Nakanishi, Naoko Obora, Akihiro Kojima, Takao Fukui, Michiaki J Diabetes Investig Original Articles BACKGROUND AND AIMS: To clarify the relationship between metabolic dysfunction‐associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). METHODS: The participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFLD was defined as having both FLD and MD, whereas CKD was defined as having an estimated glomerular filtration rate of <60 mL/min/1.73 m(2) and/or proteinuria. RESULTS: In this cross‐sectional study of 27,371 participants, the proportions of those in the non‐FLD without MD, non‐FLD with MD, FLD without MD, and MAFLD groups were 48.7, 28.2, 2.3, and 20.8%, respectively. Compared with non‐FLD without MD, MAFLD was associated with the risk of CKD (adjusted odds ratio 1.83 [1.66–2.01], P < 0.001), whereas FLD without MD was not (1.02 [0.79–1.33], P = 0.868). Moreover, compared with FLD without MD, MAFLD was associated with the risk of CKD (1.19 [1.09–1.31], P < 0.001). In this retrospective cohort study, 16,938 of 27,371 participants underwent a median 4.6 (2.0–8.1) years follow‐up, and incident data of non‐FLD without MD, non‐FLD with MD, FLD without MD, and MAFLD were 21.0, 31.1, 26.1, and 31.1 cases per 1,000 person‐years, respectively. Compared with the non‐FLD without MD, MAFLD was associated with the risk of incident CKD (adjusted hazard ratio 1.24 [1.14–1.36], P < 0.001), whereas FLD without MD was not (1.11 [0.85–1.41], P = 0.433). CONCLUSIONS: MAFLD was associated with a risk of CKD, whereas FLD without MD was not a risk for CKD. John Wiley and Sons Inc. 2021-10-12 2022-02 /pmc/articles/PMC8847128/ /pubmed/34561962 http://dx.doi.org/10.1111/jdi.13678 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Hashimoto, Yoshitaka Hamaguchi, Masahide Okamura, Takuro Nakanishi, Naoko Obora, Akihiro Kojima, Takao Fukui, Michiaki Metabolic associated fatty liver disease is a risk factor for chronic kidney disease |
title | Metabolic associated fatty liver disease is a risk factor for chronic kidney disease |
title_full | Metabolic associated fatty liver disease is a risk factor for chronic kidney disease |
title_fullStr | Metabolic associated fatty liver disease is a risk factor for chronic kidney disease |
title_full_unstemmed | Metabolic associated fatty liver disease is a risk factor for chronic kidney disease |
title_short | Metabolic associated fatty liver disease is a risk factor for chronic kidney disease |
title_sort | metabolic associated fatty liver disease is a risk factor for chronic kidney disease |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847128/ https://www.ncbi.nlm.nih.gov/pubmed/34561962 http://dx.doi.org/10.1111/jdi.13678 |
work_keys_str_mv | AT hashimotoyoshitaka metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease AT hamaguchimasahide metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease AT okamuratakuro metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease AT nakanishinaoko metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease AT oboraakihiro metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease AT kojimatakao metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease AT fukuimichiaki metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease |